Jamshedpur Reporter

Chronic Hemodialysis (CM) Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)| Key Companies – Novartis, Akebia Therapeutics

 Breaking News
  • No posts were found

Chronic Hemodialysis (CM) Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)| Key Companies – Novartis, Akebia Therapeutics

May 08
18:10 2023
Chronic Hemodialysis (CM) Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)| Key Companies - Novartis, Akebia Therapeutics
DelveInsight Business Research LLP
DelveInsight’s “Chronic Hemodialysis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic hemodialysis, historical and forecasted epidemiology as well as the Chronic hemodialysis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Chronic Hemodialysis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic hemodialysis, historical and forecasted epidemiology as well as the Chronic hemodialysis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 Chronic Hemodialysis Overview

Chronic (long-term) hemodialysis and peritoneal dialysis are used to treat children with chronic kidney failure. Acute hemodialysis is also used to treat children who have ingested certain toxins (poisons) that must be removed from the body quickly. Chronic kidney disease (CKD) is a type of kidney disease in which a gradual loss of kidney function occurs over a period of months to years. Initially, generally, no symptoms are seen, but later symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications can relate to hormonal dysfunction of the kidneys and include (in chronological order) high blood pressure (often related to activation of the renin–angiotensin system), bone disease, and anemia.

 

Chronic Hemodialysis Epidemiology Insights

The mean survival time was 46.2 months (95% CI: 41.8–50.5). The incidence of Mortality at the end of follow-up is estimated at 104 per 1000 person-years. The likelihood that these patients would survive for one and 5 years was 91% and 65%, respectively.

Click here to learn more about the Chronic Hemodialysis Market Landscape

The Report Covers the Chronic Hemodialysis Epidemiology Segmented by:

  • Total Chronic Hemodialysis incident cases 

  • Total Chronic Hemodialysis prevalent cases 

  • Total Chronic Hemodialysis treatment cases 

  • Total Chronic Hemodialysis diagnostic cases 

Chronic Hemodialysis Market Outlook 

The Chronic hemodialysis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic hemodialysis market trends by analyzing the impact of current Chronic hemodialysis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Chronic hemodialysis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic hemodialysis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chronic hemodialysis market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Chronic Hemodialysis Market

  • Novartis 

  • Akebia Therapeutics 

  • Gilead Sciences 

  • AstraZeneca 

  • Bristol Myers Squibb 

  • Merck 

  • Pfizer 

  • Abbott

And many others 

Chronic Hemodialysis Therapies Covered and Analyzed in the Report:-

  • AB002

  • DS-2330b PIB

  • Sevelamer

  • SFP

  • PEPA

  • Peginesatide

  • Sodium Zirconium Cyclosilicate 

And many others

Learn more about the Key Companies and Emerging Therapies in the Chronic Hemodialysis Market.

Table of Contents 

  1. Key Insights 

  2. Chronic Hemodialysis  Introduction 

  3. Executive Summary of Chronic Hemodialysis       

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Chronic Hemodialysis Emerging Therapies

  7. Chronic Hemodialysis Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Chronic Hemodialysis Market Outlook

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Recent Posts

Advanced Melanoma Pipeline Outlook Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Read Full Article

Categories